OxyContin Depot Forðatafla 5 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

oxycontin depot forðatafla 5 mg

mundipharma a/s - oxycodonum hýdróklóríð - forðatafla - 5 mg

OxyContin Depot Forðatafla 80 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

oxycontin depot forðatafla 80 mg

mundipharma a/s - oxycodonum hýdróklóríð - forðatafla - 80 mg

Targin Forðatafla 10 mg /5 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

targin forðatafla 10 mg /5 mg

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 10 mg /5 mg

Targin Forðatafla 20 mg /10 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

targin forðatafla 20 mg /10 mg

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 20 mg /10 mg

Targin Forðatafla 40 mg/20 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

targin forðatafla 40 mg/20 mg

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 40 mg/20 mg

Targin Forðatafla 5 mg/2,5 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

targin forðatafla 5 mg/2,5 mg

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 5 mg/2,5 mg

Thiotepa Riemser Den europeiske union - islandsk - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - Æxlishemjandi lyf - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Zutectra Den europeiske union - islandsk - EMA (European Medicines Agency)

zutectra

biotest pharma gmbh - human hepatitis b immunoglobulin - immunization, passive; hepatitis b; liver transplantation - Ónæmiskerfið sera og mótefni, - fyrirbyggja lifrarbólgu b veira (hbv) aftur sýkingu í hbsag og hbv-dna neikvæð fullorðinn sjúklingar að minnsta kosti einn viku eftir lifrarígræðslu fyrir lifrarbólgu b völdum lifrarbilun. afbrigði hbv-dna ætti að vera staðfest innan síðustu 3 mánaða fyrir olt. sjúklingar ættu að vera hbsag neikvæðar áður en meðferð hefst. samhliða nota af fullnægjandi virostatic lyf ætti að vera talin standard lifrarbólgu b aftur sýkingu fyrirbyggja.

Midodrin Evolan Tafla 2,5 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

midodrin evolan tafla 2,5 mg

evolan pharma ab - midodrinum hýdróklóríð - tafla - 2,5 mg

Midodrin Evolan Tafla 5 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

midodrin evolan tafla 5 mg

evolan pharma ab - midodrinum hýdróklóríð - tafla - 5 mg